首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126391

生殖遺傳檢測市場：策略性洞察與預測（2026-2035 年）

Reproductive Genetic Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計生殖基因檢測市場將從 2026 年的 112.1 億美元成長到 2035 年的 289.1 億美元，複合年成長率為 11.1%。

受輔助生殖技術發展、人們對遺傳疾病認知不斷提高以及非侵入性產前篩檢普及的推動，生殖遺傳檢測市場正經歷重大變革。隨著醫療專業人員和準父母們日益認知到遺傳資訊在知情生育決策、最佳化生育治療和產前風險評估中的重要性，市場正朝著貫穿整個生育過程的全面遺傳篩檢方向發展。先進的定序技術、染色體微陣列分析和人工智慧的融合，使得基因檢測更加精準、全面且日益普及。隨著生育治療的普及和人們對遺傳疾病風險認知的提高，生殖遺傳檢測計畫在醫療保健系統中不斷擴展。透過對次世代定序平台、擴展的攜帶者篩檢計畫以及人工智慧驅動的結果解讀工具的大量投資，生殖遺傳檢測正逐漸成為生殖醫學和精準醫學的關鍵組成部分。

市場促進因素

輔助生殖技術（ART）的擴展是生殖基因檢測市場的主要驅動力。由於染色體異常會影響胚胎著床結果，生育治療的成功取決於準確的基因評估。隨著高齡產婦的持續增多，體外受精（IVF）的使用率也不斷提高。隨著治療的日益複雜，對更全面的胚胎評估的需求也日益成長。生育診所正在將基因檢測納入其常規工作流程。 ART 的發展正在推動市場需求，生殖基因檢測的使用量也穩定成長。人們對遺傳疾病的認知不斷提高，透過對帶原者篩檢和產前檢測的需求，進一步加速了市場成長。由於遺傳疾病會帶來終身的臨床和經濟負擔，預防仍然是醫療保健的首要目標。準父母擴大在懷孕前尋求攜帶者篩檢。過去，由於人們對遺傳學的認知有限，預防性介入的機會也受到限制。醫療保健機構正在擴大諮詢和檢測項目。日益成長的認知正在推動市場更廣泛地採用相關技術。非侵入性產前檢測 (NIPT) 的日益普及推動了更安全的產前篩檢方法的應用。產前篩檢在妊娠管理中發揮著至關重要的作用，因為早期發現有助於改善臨床規劃。隨著醫療服務提供者尋求更安全的篩檢替代方案，NIPT 的應用也日益增加。有創操作存在手術風險，會影響患者的選擇。臨床醫生越來越推薦非侵入性方法。這一趨勢推動了對先進產前檢測的需求。基因組技術的進步提高了診斷準確性和臨床可靠性。基因檢測的準確性影響臨床可靠性，因為生育決策依賴可靠的資訊。隨著定序成本的降低和分析能力的提高，基因組技術正在不斷發展。

市場限制因素

在某些醫療保健系統中，高昂的檢測費用成為患者就醫的一大障礙。高級檢測所需的巨額費用也令部分患者望而卻步。倫理和監管方面的考量導致檢測普及程度不一。不同地區的監管方式差異為檢測機構帶來了複雜的局面。保險覆蓋範圍的不統一限制了患者獲得高級生殖遺傳檢測的機會。保險覆蓋範圍的區域差異也為患者和醫療機構帶來了不確定性。不同司法管轄區監管規定的複雜性也給尋求將新型檢測解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
生殖遺傳檢測概述
產業變化
主要市場趨勢
遺傳疾病的負擔與未滿足的臨床需求
分析篩檢和檢測的實施情況
體外受精（IVF）和輔助生殖技術（ART）利用分析
產前基因篩檢趨勢
病人歷程與臨床決策分析
實際成果值市場規模分析
市場預測分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新型基因檢測技術
產品創新分析
臨床試驗分析
管道分析
技術藍圖
人工智慧在生殖基因檢測的應用
將數位健康融入生殖醫學

第7章監理情勢

法律規範
核准流程
合規要求

第8章：生殖遺傳檢測市場：展望分析

分析：透過測試技術
分析：依檢體類型
分析：透過臨床應用
分析：依基因標記類型
分析：透過測試方法

第9章生殖遺傳檢測市場：細分市場分析

按測試類型
- 攜帶者篩檢測試
- 非侵入性產前檢測（NIPT）
- 胚胎著床前遺傳學檢測（PGT）
- 產前診斷檢測
透過技術
- 次世代定序（NGS）
- 聚合酵素鏈鎖反應（PCR）
- 染色體微陣列分析（CMA）
- 螢光原位雜合反應（FISH）
- 桑格定序
最終用戶
- 醫院
- 不孕症治療診所，體外受精（IVF）中心
- 診斷檢查室
- 學術研究機構
- 其他最終用戶

第10章：生殖遺傳檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章生殖遺傳檢測市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
中國
日本
印度
韓國
澳洲
巴西
沙烏地阿拉伯
阿拉伯聯合大公國

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

Illumina, Inc.
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Revvity, Inc.
QIAGEN NV
Natera, Inc.
Myriad Genetics, Inc.
Laboratory Corporation of America Holdings（Labcorp）
Quest Diagnostics Incorporated
BGI Genomics Co., Ltd.
CooperSurgical, Inc.
Vitrolife AB
Fulgent Genetics, Inc.
Invitae Corporation
Eurofins Scientific SE

第14章生殖遺傳檢測市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009103

The Reproductive Genetic Testing Market is anticipated to grow at a CAGR of 11.1% from USD 11.21 billion in 2026 to USD 28.91 billion in 2035.

The reproductive genetic testing market is undergoing significant transformation driven by the expansion of assisted reproductive technologies, the rising awareness of inherited disorders, and the growing adoption of non-invasive prenatal screening. The market's evolution is characterized by the shift toward comprehensive genetic screening across the reproductive journey, as healthcare providers and prospective parents increasingly recognize the importance of genetic information for informed reproductive decision-making, fertility treatment optimization, and prenatal risk assessment. The convergence of advanced sequencing technologies, chromosomal microarray analysis, and artificial intelligence is enabling more accurate, comprehensive, and increasingly accessible genetic testing. Healthcare systems are expanding reproductive genetic testing programs as fertility treatment utilization grows and awareness of hereditary disease risks expands. The market is witnessing significant investment in next-generation sequencing platforms, expanded carrier screening panels, and AI-enabled interpretation tools, positioning reproductive genetic testing as a critical component of reproductive healthcare and precision medicine.

Market Drivers

The expansion of assisted reproductive technologies represents the primary driver for the reproductive genetic testing market. Fertility treatment success depends on accurate genetic assessment because chromosomal abnormalities influence implantation outcomes. IVF utilization is increasing as delayed parenthood trends continue expanding. Treatment complexity creates demand for more comprehensive embryo evaluation. Fertility clinics are integrating genetic testing into routine workflows. ART growth strengthens market demand, resulting in sustained growth in reproductive genetic testing utilization. The rising awareness of genetic disorders is further accelerating market growth through demand for carrier screening and prenatal testing. Inherited disease prevention remains a major healthcare objective because genetic disorders create lifelong clinical and economic burdens. Prospective parents are increasingly seeking carrier screening before conception. Limited genetic awareness historically reduced preventive intervention opportunities. Healthcare providers are expanding counseling and testing programs. Increased awareness supports broader market adoption. The growth of non-invasive prenatal testing is driving adoption of safer prenatal screening approaches. Prenatal screening plays a critical role in pregnancy management because early identification improves clinical planning. NIPT adoption is increasing as healthcare providers seek safer screening alternatives. Invasive procedures create procedural risks that influence patient preferences. Clinicians are recommending non-invasive approaches more frequently. This trend strengthens demand for advanced prenatal testing. Advancements in genomic technologies are improving diagnostic accuracy and clinical confidence. Genetic testing accuracy influences clinical confidence because reproductive decisions depend on reliable information. Genomic technologies are advancing as sequencing costs decline and analytical capabilities improve.

Market Restraints

High testing costs limit accessibility in certain healthcare systems. The significant financial investment required for advanced testing creates barriers for some patients. Ethical and regulatory considerations create variability in testing adoption. Differences in regulatory approaches across regions create complexity for testing providers. Uneven reimbursement coverage constrains utilization of advanced reproductive genetic tests. Inconsistent coverage across regions creates uncertainty for patients and providers. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new testing solutions.

Technology and Product Insights

The technology landscape is characterized by the growing importance of sequencing-based platforms and comprehensive genomic analysis. NGS dominates technological adoption because it provides broad genomic coverage and high analytical sensitivity. PCR-based testing remains important for targeted applications requiring rapid analysis. Chromosomal microarray analysis continues supporting chromosomal abnormality detection. FISH remains useful in selected reproductive medicine applications. Sanger sequencing maintains relevance for confirmatory testing. The segment analysis reveals that NIPT represents a major demand segment because healthcare providers increasingly prefer safer prenatal screening approaches. Carrier screening utilization is expanding as prospective parents seek preconception risk assessment. PGT demand is increasing because IVF programs seek improved embryo selection outcomes. Prenatal diagnostic testing continues supporting confirmatory analysis in high-risk pregnancies. Fertility clinics and IVF centers represent a major demand segment because reproductive genetic testing is increasingly integrated into fertility treatment workflows. Diagnostic laboratories continue expanding testing capabilities as genetic screening volumes increase. Hospitals support prenatal testing and maternal-fetal medicine applications. The integration of AI is becoming increasingly important because genomic datasets continue expanding. AI-supported interpretation tools are gaining importance as healthcare providers require efficient analysis.

Competitive and Strategic Outlook

The competitive landscape features established sequencing and diagnostics companies alongside specialized reproductive health, fertility, and genetic testing providers. Illumina remains strategically distinct because it provides foundational sequencing technologies supporting a large portion of reproductive genetic testing workflows, benefiting from extensive NGS adoption and strong relationships across clinical laboratories. Roche leverages genomic diagnostics expertise to support reproductive health applications, focusing on molecular testing innovation and analytical performance. Thermo Fisher supports reproductive genetics through sequencing technologies, laboratory solutions, and genomic analysis tools. Revvity maintains relevance through reproductive health and newborn screening expertise, focusing on improving diagnostic efficiency and expanding genomic testing capabilities. QIAGEN differentiates itself through molecular testing and sample preparation technologies, with solutions supporting reproductive genetics workflows. Natera focuses strongly on reproductive health and remains a prominent participant in NIPT and carrier screening markets. Myriad Genetics supports reproductive testing through carrier screening and hereditary disease assessment services. Labcorp leverages extensive laboratory infrastructure and broad diagnostic capabilities. Companies are pursuing product portfolio expansion through innovation in NIPT platforms, carrier screening panels, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers, fertility clinics, and research institutions are increasing, driven by the need for comprehensive reproductive genetic testing. Recent key developments include Myriad Genetics announcing the full commercial launch of its FirstGene Multiple Prenatal Screen. BGI Genomics introduced SIROmics AI-Powered Localized Solution for High-throughput Genetic Testing. 3billion announced the launch of Family Insight Test. Natera announced the launch of Natera's expanded 21-gene Fetal Focus single gene non-invasive prenatal test. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where fertility infrastructure is expanding.

Short Conclusion

The reproductive genetic testing market is positioned for sustained growth driven by the convergence of fertility treatment expansion, genetic awareness, and technological innovation. The transition from limited genetic screening toward comprehensive genomic assessment across the reproductive journey represents a fundamental shift in reproductive healthcare. While challenges related to high costs, ethical considerations, and reimbursement variability persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with reproductive genetic testing evolving into a critical component of reproductive healthcare, supporting informed decision-making, fertility treatment optimization, and improved maternal and fetal health outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Reproductive Genetic Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Overview of Reproductive Genetic Testing
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Burden of Genetic Disorders & Unmet Clinical Needs
3.6 Screening and Testing Adoption Analysis
3.7 IVF and Assisted Reproductive Technology (ART) Utilization Analysis
3.8 Prenatal Genetic Screening Trends
3.9 Patient Journey and Clinical Decision-Making Analysis
3.10 Historical Market Size Analysis (2021-2025)
3.11 Market Forecast Analysis (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Genetic Testing Technologies
6.2 Product Innovation Analysis
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Technology Roadmap
6.6 AI Integration in Reproductive Genetic Testing
6.7 Digital Health Integration in Reproductive Medicine

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Reproductive Genetic Testing Market Landscape Analysis

8.1 Analysis by Testing Technology
8.2 Analysis by Sample Type
8.3 Analysis by Clinical Application
8.4 Analysis by Genetic Marker Type
8.5 Analysis by Testing Methodology

9. Reproductive Genetic Testing Market Segment Analysis (2021-2035)

9.1 By Test Type
- 9.1.1 Carrier Screening Tests
- 9.1.2 Non-Invasive Prenatal Testing (NIPT)
- 9.1.3 Preimplantation Genetic Testing (PGT)
- 9.1.4 Prenatal Diagnostic Testing
9.2 By Technology
- 9.2.1 Next-Generation Sequencing (NGS)
- 9.2.2 Polymerase Chain Reaction (PCR)
- 9.2.3 Chromosomal Microarray Analysis (CMA)
- 9.2.4 Fluorescence In Situ Hybridization (FISH)
- 9.2.5 Sanger Sequencing
9.3 By End User
- 9.3.1 Hospitals
- 9.3.2 Fertility Clinics & IVF Centers
- 9.3.3 Diagnostic Laboratories
- 9.3.4 Academic & Research Institutes
- 9.3.5 Other End Users